Delving into the Latest Updates on Azelastine Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

4-(p-Chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-phthalazinone, Afluon, Allergodil

+ [29]

Target

H1 receptor

Action

antagonists, stabilizers

Mechanism

H1 receptor antagonists(Histamine H1 receptor antagonists), Mast cells stabilizers

Therapeutic Areas

Immune System DiseasesInfectious DiseasesOtorhinolaryngologic Diseases+ [2]

Active Indication

Respiratory Tract InfectionsRhinitis, Allergic, PerennialRhinitis, Allergic, Seasonal+ [7]

Inactive Indication

Chronic rhinitisConjunctivitis, AllergicPerennial allergic conjunctivitis+ [2]

Originator Organization

Active Organization

+ [2]

Inactive Organization

Meda Pharmaceuticals, Inc.NORVIUM BIOSCIENCE

Bayer AG

Drug Highest PhaseApproved

First Approval Date

Japan (30 Apr 1986),

AsthmaRhinitis, Allergic

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC22H25Cl2N3O

InChIKeyYEJAJYAHJQIWNU-UHFFFAOYSA-N

CAS Registry79307-93-0

Randomized, Double-blind, Cross-over Clinical Trial to Assess Onset of Action and Efficacy of Azelastine Hydrochloride 0.15% Nasal Spray in the Treatment of Allergen-Induced Allergic Rhinitis Symptoms in an Environmental Exposure Unit in Comparison to Placebo and Mometasone Furoate/Olopatadine Hydrochloride Nasal Spray

This study is to assess the Onset of Action and Efficacy of azelastine hydrochloride 0.15% in treating the nasal symptoms of seasonal allergic rhinitis (SAR) induced by an allergen challenge in an Environmental Exposure Unit (EEU) followed by a single dose and a 3-day treatment at home.

Start Date30 Oct 2023

Sponsor / Collaborator

Meda Pharma GmbH & Co. KG

NCT05887843

/ TerminatedPhase 1

An Open-label, Single-Dose, Three-way Crossover Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents (12 to 17 Years of Age) and Young Adults (18 to 24 Years of Age) With Seasonal Allergic Rhinitis

This study will compare the PK parameters of the combination test formulation to monotherapy reference products (mometasone furoate and azelastine hydrochloride) in adolescents and young adult patients with seasonal allergic rhinitis.

Start Date08 Jun 2023

Sponsor / Collaborator

Sandoz International GmbH

100 Clinical Results associated with Azelastine Hydrochloride

Login to view more data

100 Translational Medicine associated with Azelastine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Azelastine Hydrochloride

Login to view more data

872

Literatures (Medical) associated with Azelastine Hydrochloride

01 Mar 2025·CLINICAL AND EXPERIMENTAL ALLERGY

Adherence to Treatment in Allergic Rhinitis During the Pollen Season in Europe: A MASK‐air Study

Article

Author: Cherrez‐Ojeda, Ivan ; Haahtela, Tari ; Robles‐Velasco, Karla ; Kvedariene, Violeta ; Bousquet, Jean ; Fonseca, Joao A. ; Klimek, Ludger ; Devillier, Philippe ; Larenas‐Linnemann, Desiree E. ; Zuberbier, Torsten ; Sousa‐Pinto, Bernardo ; Costa, Elísio M. ; Morais‐Almeida, Mario ; Czarlewski, Wienczyslawa ; Iinuma, Tomohisa ; Reitsma, Sietze ; Patella, Vincenzo ; Kraxner, Helga ; Canonica, G. Walter ; Ventura, Maria Teresa ; Pham‐Thi, Nhân ; Sastre, Joaquin ; Makris, Michael ; Niedoszytko, Marek ; Kuna, Piotr ; Brussino, Luisa ; Amaral, Rita ; Del Giacco, Stefano ; Regateiro, Frederico S. ; Laune, Daniel ; Toppila‐Salmi, Sanna K. ; Yorgancioglu, Arzu ; Sova, Milan ; Zidarn, Mihaela ; Taborda‐Barata, Luis ; Cecchi, Lorenzo ; Cardona, Victoria ; Pfaar, Oliver ; Papadopoulos, Nikolaos G. ; Fokkens, Wytske J. ; Louis, Renaud ; Pereira, Ana Margarida ; Vieira, Rafael José ; Ansotegui, Ignacio J. ; Rouadi, Philip W. ; Cingi, Cemal ; Cruz, Alvaro A. ; Samolinski, Boleslaw ; Bergmann, Karl C. ; Ivancevich, Juan Carlos ; Gemicioglu, Bilun ; Valiulis, Arunas ; Bedbrook, Anna ; Mösges, Ralph

ABSTRACT:

Background:

Adherence to rhinitis treatment has been insufficiently assessed. We aimed to use data from the MASK‐air mHealth app to assess adherence to oral antihistamines (OAH), intra‐nasal corticosteroids (INCS) or azelastine‐fluticasone in patients with allergic rhinitis.

Methods:

We included regular European MASK‐air users with self‐reported allergic rhinitis and reporting at least 1 day of OAH, INCS or azelastine‐fluticasone. We assessed weeks during which patients answered the MASK‐air questionnaire on all days. We restricted our analyses to data provided between January and June, to encompass the pollen seasons across the different assessed countries. We analysed symptoms using visual analogue scales (VASs) and the combined symptom‐medication score (CSMS), performing stratified analyses by weekly adherence levels. Medication adherence was computed as the proportion of days in which patients reported rhinitis medication use. Sensitivity analyses were performed considering all weeks with at most 1 day of missing data and all months with at most 4 days of missing data.

Results:

We assessed 8212 complete weeks (1361 users). Adherence (use of medication > 80% days) to specific drug classes ranged from 31.7% weeks for azelastine‐fluticasone to 38.5% weeks for OAH. Similar adherence to rhinitis medication was found in users with or without self‐reported asthma, except for INCS (better adherence in asthma patients). VAS and CSMS levels increased from no adherence to full adherence, except for INCS. A higher proportion of days with uncontrolled symptoms was observed in weeks with higher adherence. In full adherence weeks, 41.2% days reported rhinitis co‐medication. The sensitivity analyses displayed similar results.

Conclusions:

A high adherence was found in patients reporting regular use of MASK‐air. Different adherence patterns were found for INCS compared to OAH or azelastine‐fluticasone that are likely to impact guidelines.

01 Mar 2025·Asia Pacific Allergy

Efficacy and safety of azelastine hydrochloride and fluticasone propionate nasal spray in treating allergic rhinitis: A randomized controlled trial

Article

Author: Zhang, Luo ; Zhang, Qinna ; Hu, Guohua ; Wang, Chengshuo ; Li, Huabin ; Xing, Zhimin ; Han, Xinling ; Gao, Xiaoping ; Li, Lingbo ; Liu, Dingrong ; Xia, Jiao ; Liu, Jixiang ; Wan, Lijia ; Xiao, Shuifang ; Huang, Xinsheng ; Zhou, Huifang ; Bian, Tao ; Qu, Shenhong ; Meng, Juan ; Zhao, Changqing ; Ma, Huaan ; Xie, Jinghua ; Zhang, Hua ; Zhu, Li ; Guan, Bing ; Lin, Chang ; Jiang, Qingshan ; Li, Xianhua ; Shi, Haiyun ; Li, Chao ; Zhang, Yuan ; Tang, Jinyong ; Tan, Guolin ; Yu, Yafeng

Background::

MP-AzeFlu (Dymista; Meda Pharma GmbH & Co., KG), a formulation combining azelastine hydrochloride and fluticasone propionate in a single spray, is superior to fluticasone propionate alone in relieving symptoms and improving the quality of life of patients with allergic rhinitis.

Objectives::

In this study, we evaluated whether the effect of AzeFlu, a generic drug manufactured from China, is equivalent to that of MP-AzeFlu.

Methods::

In total, 679 patients were recruited for a multicentre, randomized, double-blind, original drug-controlled, and parallel-group clinical trial. Overall, 339 and 340 patients were administered with AzeFlu and MP-AzeFlu, respectively. Efficacy was assessed by changes in the reflective total nasal symptom score, the area under the curve of reflective total nasal symptom score changes over time, changes from baseline in individual nasal symptom scores, and the Rhinoconjunctivitis Quality of Life Questionnaire. In addition, a safety evaluation was simultaneously performed.

Results::

AzeFlu and MP-AzeFlu reduced the reflective total nasal symptom score from baseline (AzeFlu −6.7 [standard deviation, 2.59]; MP-AzeFlu −6.7 [standard deviation, 2.76]; P = 0.905) and improved nasal symptoms and quality of life (AzeFlu −62.3 [standard deviation, 33.59]; MP-AzeFlu −64.7 [standard deviation, 33.73]; P = 0.394) in patients with allergic rhinitis. Significant differences were not observed between groups.

Conclusion::

AzeFlu showed effects equivalent to those of MP-AzeFlu in this clinical trial and may benefit Chinese patients with allergic rhinitis.Registration number: CTR20190189 (chinadrugtrials.org.cn/index.html)

01 Mar 2025·Clinical Pharmacology in Drug Development

Determination of the Bioavailability of 3 Intranasal Formulations of Azelastine Hydrochloride in Healthy Male Volunteers

Article

Author: Nguyen, Duc Tung ; Berger, William E. ; Bousquet, Jean ; Canonica, Georgio Walter ; Liu, Mark ; Klimek, Ludger ; Ramalingam, Rajesh Kumar

Abstract:

The primary objective of the study was to determine the bioavailability of 2 new formulations of azelastine (AZE) hydrochloride (0.10% and 0.15% AZE) containing sorbitol and sucralose compared with the commercially available 0.10% AZE. This study was performed in healthy volunteers based on the pharmacokinetic parameters maximum plasma concentration and area under the plasma concentration–time curve from time zero to the last measurable concentration. This was a Phase 1, open‐label, single‐center, randomized, parallel‐group study. Subjects were randomized to 1 of 3 treatment groups: (1) 0.10% AZE (treatment A), (2) 0.15% AZE (treatment B) (Groups 1 and 2 both containing sorbitol and sucralose), and (3) the commercially available 0.10% AZE (treatment C). A total of 54 subjects were randomized and received treatment A, B, or C. Maximum plasma concentration and area under the plasma concentration–time curve were similar when compared in treatments A and C (0.1%) for AZE and its metabolite, desmethylazelastine. The most frequently reported adverse events were rhinorrhea (5.6%) and sneezing (5.6%).

10

News (Medical) associated with Azelastine Hydrochloride

04 Jul 2024

·www.pharmaceutical-technology.com

Viatris closes $3.37bn divestitures with OTC deal

Viatris completed the last of its $3.37bn divestitures, signing a deal with Cooper Consumer Health to transfer of its OTC business. Credit: SOPA Images via Getty Images. Viatris announced the finalisation of a transaction to divest its over-the-counter (OTC) business, completing the last step in its previously declared $3.37bn divestitures. The US-headquartered company divested its entire OTC business to Cooper Consumer Health, a European OTC drug manufacturer, on 3 July. In the agreement, Cooper Consumer Health has gained access to two manufacturing plants based in Merignac, France; and Confienza, Italy, and a research and development site in Monza, Italy. In its strategic plan, Viatris retained the rights for its blockbuster generic drugs Viagra (sildenafil) and Dymista (azelastine hydrochloride and fluticasone propionate) alongside certain other OTC therapies. Viatris first spread word of the OTC divestiture in October 2023 declaring definitive agreements to divest other areas of the company. Over the last few months, the nutraceutical company Matrix Pharma Private gained access to Viatris’ active pharmaceutical ingredients division and Spanish pharmaceutical company Insud Pharma acquired Viatris’ women’s health business. The latter deal gave Insud Pharma two manufacturing plants in India. Furthermore, a December 2023 definitive agreement transferred Viatris’ European rights for therapies such as Duphaston (Dydrogesterone) and Femoston (estradiol) to Theramex . The generics company also divested commercialisation rights in some non-core markets that were acquired, when Viatris was formed through the combination of Mylan and UpJohn. As per a 3 July press release, Viatris made the various divestitures to help achieve its “long-term gross leverage target” and “increase shareholder return through share buybacks and dividends”. The generics company also plans to use the money to acquire, develop and commercialise more therapies in the future. Last year, the company generated a total revenue of $15.4bn, reaching a free cash flow of $2.4bn. By 28 January 2024, the company had already completed $250m in share repurchases for this year. See Also: Left in limbo: When pharma halts rare disease research The pathway to preventative health: How pharma can support the NHS Long Term Plan In November 2022, Viatris released a strategic update detailing a two-stage plan for business growth with plans to end Phase I by the end of this year and execute Phase II between 2024 and 2028. In the first phase, the company aimed to complete all planned divestitures, have seven consecutive quarters of strong performance and continue progress on key science programmes among other things. At the January 2024 JP Morgan Healthcare Conference, Viatris announced that it had achieved its goals for Phase I and will be advancing to Phase II, which prioritises the growth of the company’s ophthalmology division and prevention of base business erosion.

AcquisitionPhase 2

09 Jan 2024

·synapse.patsnap.com

Deciphering H1 receptor antagonists and Keeping Up with Their Recent Developments

The H1 receptor, also known as the histamine H1 receptor, plays a crucial role in the human body. It is primarily found in smooth muscle cells, endothelial cells, and nerve cells. Activation of the H1 receptor by histamine leads to various physiological responses, including vasodilation, increased vascular permeability, bronchoconstriction, and stimulation of sensory nerve endings. These responses are involved in allergic reactions, inflammation, and immune responses. Antagonists of the H1 receptor, commonly known as antihistamines, are widely used to treat allergies, hay fever, and other conditions associated with excessive histamine release. Understanding the role of the H1 receptor is essential for developing effective treatments for allergic and inflammatory disorders. The analysis of the target H1 receptor reveals a competitive landscape with multiple companies actively developing drugs. GSK Plc, Sanofi, Pfizer Inc., Bayer AG, and Novartis AG are among the companies with the highest number of approved drugs or drugs in advanced stages of development. The indications with the most approved drugs include Common Cold, Rhinitis, Allergic, Urticaria, Pruritus, and Hypersensitivity. Small molecule drugs are the most rapidly progressing drug type, indicating intense competition in this area. China, the United States, and Japan are the countries with the highest number of approved drugs, with China showing significant progress in the development of drugs targeting the H1 receptor. Overall, the target H1 receptor presents opportunities for further research and development, particularly in indications with high unmet medical needs. How do they work?H1 receptor antagonists, also known as H1 blockers or antihistamines, are a class of drugs that block the action of histamine at the H1 receptor. Histamine is a chemical released by the body during an allergic reaction, causing symptoms such as itching, sneezing, runny nose, and watery eyes. H1 receptor antagonists work by binding to the H1 receptors on cells, preventing histamine from binding and exerting its effects. From a biomedical perspective, H1 receptor antagonists are commonly used to treat allergic conditions, such as hay fever (allergic rhinitis), hives (urticaria), and allergic conjunctivitis. They help alleviate symptoms by reducing the effects of histamine, thereby relieving itching, sneezing, and other allergic reactions. There are different generations of H1 receptor antagonists, each with varying degrees of sedative effects. First-generation antihistamines, such as diphenhydramine and chlorpheniramine, can cause drowsiness and are often used for their sedative properties in addition to their antihistamine effects. Second-generation antihistamines, such as cetirizine, loratadine, and fexofenadine, are less likely to cause sedation and are preferred for daytime use. In summary, H1 receptor antagonists are drugs that block the action of histamine at the H1 receptor, providing relief from allergic symptoms. They are commonly used in the treatment of various allergic conditions and come in different generations with varying sedative effects. List of H1 receptor AntagonistsThe currently marketed H1 receptor antagonists include: Olopatadine Hydrochloride/Mometasone Furoate MonohydrateChlorpheniramine Maleate/Codeine PhosphateDiphenhydramine Hydrochloride/Naproxen SodiumRecombinant interferon alfa-2b/LoratadineRupatadine FumarateAzelastine/mometasoneEbastine/Pseudoephedrine HydrochlorideAzelastine Hydrochloride/Fluticasone PropionateChlorpheniramine Maleate/Hydrocodone Bitartrate/Pseudoephedrine HydrochlorideAlcaftadineFor more information, please click on the image below. What are H1 receptor antagonists used for?H1 receptor antagonists are widely used to treat allergies, hay fever, and other conditions associated with excessive histamine release. For more information, please click on the image below to log in and search. How to obtain the latest development progress of H1 receptor antagonists?In the Synapse database, you can keep abreast of the latest research and development advances of H1 receptor antagonists anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

19 Jul 2023

·www.fiercepharma.com

Pharma brands make the biggest splash for TV ad debuts so far this year

Bayer’s OTC antihistamine Astepro took the top spot, but new prescription meds from Big Pharma also had a strong showing. Pharmaceutical drugs made up half of the most-seen new brands by TV ad impressions for the first half of 2023 as the industry looks to boost awareness of its newest offerings. That’s according to a new report shared with Fierce Pharma Marketing by real-time ad tracker iSpot.TV. The report, which covered ad impressions for the first half of this year, found that pharma brands dominated the top 10 new brands with the highest ad impressions for TV airtime. In fact, pharma brands occupied five out of those spots including the top three positions. In at No. 1 was Bayer’s OTC antihistamine Astepro, with the German Big Pharma clearly capitalizing on the strong hay fever season this year. That drug saw 7.39 billion TV ad impressions, according to iSpot’s data, by far the most of all new brands, with NBC being its top network. At No. 2 was AbbVie's immunology drug Skyrizi, which recorded just over 6 billion TV ad impressions specifically for its Crohn's disease label. Additionally, NBC proved to be its largest network in terms of ad impressions. This year, Skyrizi is competing to have the highest ad spend among all prescription products. AbbVie is aiming to make up for the declining revenue it's experiencing from its aging blockbuster drug Humira. In third place is Bristol Myers Squibb’s newly approved plaque psoriasis med Sotyktu with 4.3 billion impressions in the first half of this year. ABC was its biggest network in terms of ad impressions. That dermatology med debuted at the Grammys earlier this year with the spot “Found It,” which focuses on two people who have cleared their skin and gained confidence thanks to Sotyktu, a once-a-day pill approved by the FDA last fall. The next Big Pharma drug comes in at eighth place with Eli Lilly’s blockbuster-in-waiting diabetes therapy Mounjaro, with just over 3 billion TV ad impressions and ABC as its largest network. Lilly launched a direct-to-consumer campaign this year for Mounjaro, which received FDA approval in May 2022. Since its advertisement launch in April, the therapy has consistently ranked among the top 10 pharmaceutical TV drug ad spenders. That could jump even more next year as Lilly is angling for the drug to nab a second approval in obesity, which could launch a major market battle with rival Novo Nordisk and its new obesity therapy Wegovy. Rounding off the pharma top five, and in ninth place overall, is AbbVie’s Skyrizi once again, but this time for its psoriatic arthritis indication, with 2.96 billion impressions and NBC as its top network.

Drug Approval

100 Deals associated with Azelastine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00659	Azelastine Hydrochloride	R01AC03 R06AX19 S01GX07	DB00972

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Respiratory Tract Infections	United States	Bayer HealthCare AG	17 Jun 2021
Rhinitis, Allergic, Perennial	Australia	Viatris Pty Ltd.	21 Jul 2004
Conjunctivitis, Allergic	United States	NORVIUM BIOSCIENCE	22 May 2000
Rhinitis, Allergic, Seasonal	United States	NORVIUM BIOSCIENCE	01 Nov 1996
Rhinitis, Vasomotor	United States	NORVIUM BIOSCIENCE	01 Nov 1996
Dermatitis	Japan	Eisai Co., Ltd.	30 Aug 1990
Eczema	Japan	Eisai Co., Ltd.	30 Aug 1990
Prurigo	Japan	Eisai Co., Ltd.	30 Aug 1990
Pruritus	Japan	Eisai Co., Ltd.	30 Aug 1990
Urticaria	Japan	Eisai Co., Ltd.	30 Aug 1990
Asthma	Japan	Eisai Co., Ltd.	30 Apr 1986
Rhinitis, Allergic	Japan	Eisai Co., Ltd.	30 Apr 1986

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Seasonal rhinitis	Phase 3	United States	Meda Pharmaceuticals, Inc.	01 Jul 2013
Perennial allergic conjunctivitis	Phase 3	United States	Meda Pharmaceuticals, Inc.	01 Jan 2007
Chronic rhinitis	Phase 3	United States	Meda Pharmaceuticals, Inc.	01 Jul 2006

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04264637 (Pubmed \| Ann Allergy Asthma Immunol) Manual	Phase 3	Rhinitis, Allergic	110	Azelastine HCl 0.15% nasal spray	jwhdcnzyck(gkehyjyuqr) = irhkyijfmj ugzttwbacl (jxzbwvplsh )	Positive	01 Jul 2024
AAAAI2024	Not Applicable	Rhinitis, Allergic, Perennial Maintenance	87	Fluticasone propionate/azelastine (FP/Aze 50/137 μg each nostril twice daily)	oemfjvmbuo(bfvkywmtvj): mean difference = 1.26 (95% CI, 0.59 - 1.93), P-Value = <0.001	Positive	23 Feb 2024
				Fluticasone furoate (FF 55 μg each nostril once daily)
NCT03599791 (Pubmed \| Pulm Ther)	Phase 3	Rhinitis, Allergic	900	MP-AzeFlu nasal spray	oofuptixsp(atkilhuzhh): P-Value = 0.0007 View more	-	01 Sep 2023
				Fluticasone propionate nasal spray
NCT00712920 (Pubmed)	Phase 3	Rhinitis, Allergic, Perennial	581	0.10% Azelastine hydrochloride	plizhhnbcf(mxjincqftt) = mfxajdrlwf xfxfrzkemb (fkozciidtp, 3.99)	Positive	01 Jan 2023
				0.15% Azelastine hydrochloride	plizhhnbcf(mxjincqftt) = cvbyixqhrc xfxfrzkemb (fkozciidtp, 4.26)
ONSET OF ACTION OF AZELASTINE HCL NASAL SPRAY 0.15% (ACAAI2022)	Not Applicable	-	110	Azelastine HCl 0.15%	eshapfhhen(oucfnmzfol) = qvttvpzsfp eisjncsgvf (dublajvbjx )	Positive	10 Nov 2022
Pubmed Manual	Phase 4	Conjunctival Diseases	111	Fluorometholone+Azelastine	werlvjjnwa(rsofnehhce) = vraqhrvugp jrrrvgnbgi (xpvupnfnyg, 2.19) View more	Positive	04 Jul 2022
				Fluorometholone	werlvjjnwa(rsofnehhce) = bbvpwswnxj jrrrvgnbgi (xpvupnfnyg, 8.46) View more
AAAAI2018	Not Applicable	Rhinitis, Allergic	-	Fluticasone propionate/Azelastine hydrochloride	cafiqupmlv(jpokmjhdof) = lueuahyvlx kiozhtnyvd (ooxrjmkxow )	-	01 Feb 2018
				Fluticasone propionate	cafiqupmlv(jpokmjhdof) = sniqqgekrx kiozhtnyvd (ooxrjmkxow )
NCT01915823 (CTgov)	Phase 3	Rhinitis, Allergic, Seasonal \| Seasonal rhinitis	348	azelastine hydrochloride (Dymista)	mytgwxdwwc(yaqliowpmu) = kmxfpmukqf ppitihrchr (aefbfznbxs, 5.154) View more	-	29 Jun 2015
				Dymista vehicle (Dymista Vehicle)	mytgwxdwwc(yaqliowpmu) = suyboegohi ppitihrchr (aefbfznbxs, 4.731) View more
NCT01880840 (CTgov)	Phase 4	Rhinitis, Allergic	191	205.5 mcg of azelastine hydrochloride (Astepro 0.15% Nasal Spray)	siekbqbcpw = hezbtwdrch kjuwfmqvei (hwwpiszkgm, cfairjkeol - jxwuvqzdji) View more	-	29 Jun 2015
				137 mcg of azelastine hydrochloride (Astepro 0.1% Nasal Spray)	siekbqbcpw = fhgbvahumx kjuwfmqvei (hwwpiszkgm, pejjlkujcp - pfxpueypfs) View more
NCT01018862 (CTgov)	Phase 3	Rhinitis, Allergic, Perennial	489	Azelastine hydrochloride nasal spray 0.15% (MP03-36 (0.15% Solution))	qbanmrjqei(rlzmzutewm) = nrhpojlsdf lfzryeqrof (dejiaqqvcq, 4.03) View more	-	11 Jun 2012
				Azelastine hydrochloride nasal spray 0.10% (MP03-33 (0.10% Solution))	qbanmrjqei(rlzmzutewm) = cumlwuzfrt lfzryeqrof (dejiaqqvcq, 4.37) View more